ARCA biopharma, Inc.
(NASDAQ : ABIO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-2.38%275.201.4%$809.08m
AMGNAmgen, Inc.
-0.56%217.001.3%$492.24m
CELGCelgene Corp.
-0.48%109.881.3%$454.50m
GILDGilead Sciences, Inc.
0.00%63.331.0%$379.06m
ILMNIllumina, Inc.
0.02%298.293.5%$303.29m
VRTXVertex Pharmaceuticals, Inc.
-1.24%204.531.9%$296.06m
REGNRegeneron Pharmaceuticals, Inc.
-2.36%340.092.6%$258.39m
EXASEXACT Sciences Corp.
2.09%79.8924.0%$198.96m
ALXNAlexion Pharmaceuticals, Inc.
-1.62%105.402.0%$180.23m
SGENSeattle Genetics, Inc.
-0.13%112.066.1%$131.37m
BMRNBioMarin Pharmaceutical, Inc.
-0.71%75.604.3%$115.42m
SRPTSarepta Therapeutics, Inc.
-3.38%97.5914.6%$111.53m
AAgilent Technologies, Inc.
-0.35%76.891.6%$100.75m
MRTXMirati Therapeutics, Inc.
1.65%102.392.3%$88.04m
NBIXNeurocrine Biosciences, Inc.
-1.18%109.605.0%$84.66m

Company Profile

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company engages in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.